Estimates of the True Number of Cases of Pandemic (H1N1) 2009, Beijing, China by Wang, Xiaoli et al.
Estimates of the 
True Number   
of Cases of 
Pandemic (H1N1) 
2009, Beijing, China
Xiaoli Wang, Peng Yang, Holly Seale, Yi Zhang, 
Ying Deng, Xinghuo Pang, Xiong He,  
and Quanyi Wang
During  2009,  a  total  of  10,844  laboratory-confirmed 
cases of pandemic (H1N1) 2009 were reported in Beijing, 
People’s Republic of China. However, because most cas-
es were not confirmed through laboratory testing, the true 
number is unknown. Using a multiplier model, we estimated 
that ≈1.46–2.30 million pandemic (H1N1) 2009 infections 
occurred. 
I
nfection with a novel swine-origin influenza A (H1N1) 
virus,  currently  named  pandemic  (H1N1)  2009  virus, 
first occurred in the United States and Mexico in early April 
2009 (1,2) and then rapidly spread to other regions of the 
world. As the outbreak expanded, laboratory testing of per-
sons with suspected cases became increasingly impractical, 
extremely resource intensive, and was discontinued. We 
assume, therefore, that the number of laboratory-confirmed 
cases represents only a small fraction of the actual number 
of infections (3–5). In this study, we used a multiplier mod-
el to estimate the true number of cases of pandemic (H1N1) 
2009 in Beijing, People’s Republic of China.
The Study
To estimate the prevalence of pandemic (H1N1) 2009 
in the United States, the US Centers for Disease Control 
and  Prevention  (CDC)  developed  a  software  program 
(Impact2009, version 1.0) (6) based on the Monte Carlo 
approach and the multiplier model. Although this simple 
and useful program can be used to estimate the true num-
ber of cases in the United States, it may not be so readily 
applied to other countries because of uncertainties in the 
model parameters. To account for these uncertainties, in 
this study we decided to alter the way in which the base-
line data assumptions were calculated. For example in the 
original CDC model, the prevalence was calculated on the 
basis of the laboratory-confirmed case data. In contrast, 
we calculated the baseline case number by multiplying 
the reported number of influenza-like illness (ILI) cases 
in secondary and tertiary hospitals by the positive rate of 
pandemic (H1N1) 2009 among ILI cases. We obtained 
this information from the Beijing influenza surveillance 
system, which encompasses data on ILI cases from all 
secondary and tertiary hospitals (levels 2, 3) and virologic 
surveillance data (7).
From the virologic surveillance data, we determined 
that positive cases of pandemic (H1N1) 2009 were identi-
fied through August 3, 2009. From this finding, we used 
2 phases for the model: phase 1 (May 16, 2009, through 
August 2, 2009) and phase 2 (August 3, 2009 through De-
cember 31, 2009). In addition, the consultation rate for ILI 
cases had changed over the course of the pandemic, be-
cause of changes in strategies used to control the disease 
in Beijing before and after National Day (October 1). To 
adjust for the introduction of these strategies, we further 
divided phase 2 into 2 periods: period 2a (from August 3, 
2009, through September 30, 2009) and period 2b (from 
October 1, 2009, through December 31, 2009).
During phase 1, the number of laboratory-confirmed 
cases was considered to reflect the true number of pandem-
ic (H1N1) 2009 infections. However, during phase 2, we 
calculated the true number of infections by multiplying the 
baseline by the estimation coefficient, using the multiplier 
model. In this multiplier model, the baseline case number 
was equal to the sum of the product of the weekly ILI case 
number in level 2 and 3 hospitals and the corresponding 
weekly pandemic (H1N1) 2009 positive rate among case-
patients with ILIs. The estimation coefficient was found by 
multiplying the reciprocal of the parameters in the model. 
The following parameters were required in our estimation: 
the proportion of symptomatic infection among patients 
with cases of pandemic (H1N1) 2009, the proportion of 
ILI among patients with symptomatic cases of pandemic 
(H1N1)  2009,  the  consultation  rate  among  ILI  case-pa-
tients, the sampling success rate, and the sensitivity of the 
test (Figure; Table 1). These terms were obtained from a 
review of the literature (8–12) and from recommendations 
by health professionals. We assumed that the consultation 
rate of ILIs in each of the 2 periods was consistent and that 
the syndromic profile of pandemic (H1N1) 2009 did not 
change greatly.
In phase 1, a total of 325 positive cases were report-
ed (considered as the true infection number). In period 2a 
and period 2b of phase 2, the baseline case numbers were 
6,520 and 171,899, respectively. During phase 2, a total of 
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1,800,074 pandemic (H1N1) 2009 infections were estimat-
ed. Thus, by the end of 2009, the cumulative number of per-
sons infected with pandemic (H1N1) 2009 in Beijing was 
estimated to be 1,800,399 (90% range 1.46–2.30 million)   
(Table 2). However, only 10,844 laboratory-confirmed cas-
es were reported during the same period. One laboratory-
confirmed case equaled 166 (90% range 135–212) infec-
tions in reality. According to the population size of Beijing, 
the overall infection rate was 10.6%. The highest infection 
rate was recorded in those 5–14 years of age (31.8%), fol-
lowed by those 0–4 years of age (30.8%) (Table 2). In com-
parison, the rate in persons >60 years was only 0.9%.
Conclusion
Despite  the  small  number  of  laboratory-confirmed 
cases (10,844), we estimated that the actual number of 
persons infected with pandemic (H1N1) 2009 was 1.8 mil-
lion in Beijing by the end of 2009. Previous studies have 
claimed that the number of laboratory-confirmed cases of 
pandemic (H1N1) 2009 was substantially underestimated, 
reflecting only a very small fraction of the actual infec-
tions (3–5). This study also demonstrated that school age 
children were more likely to be infected with pandemic 
(H1N1) 2009. However, those >60 years of age were at 
low risk for infection.
From  November  27  through  December  7,  2009,  a 
serologic survey to establish the prevalence of pandemic 
(H1N1) 2009 antibody was conducted in the general pop-
ulation  of  Beijing.  The  results  showed  that  ≈14%–15% 
(13) of the general population had antibodies to pandemic 
(H1N1) 2009 virus. Based on the population size of 17 mil-
lion in Beijing in 2009 (14) and the assumption that an-
tibodies against pandemic (H1N1) 2009 virus are usually 
produced after 2 weeks of infection or vaccination (15), we 
estimated that 2.37 to 2.54 million persons were infected 
with  pandemic  (H1N1)  2009  virus  as  of  November  13, 
2009. According to data from the Beijing Center for Dis-
ease Prevention and Control, by November 13, 2009, 1.36 
million persons had received the pandemic (H1N1) 2009 
vaccine.  After  the  vaccinated  population  were  removed 
from the equation, the total number of pandemic (H1N1) 
  Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 16, No. 11, November 2010  1787 
Figure. Model parameters for estimating the true number of persons 
infected with pandemic (H1N1) 2009 in Beijing. A, hospitals refer to 
level 2 and 3 hospitals in Beijing; B, sampling success rate was 
included in the model because not all actual positive specimens 
gave  positive  results  because  of  the  timing  of  collection  or  the 
quality  of  the  specimen;  C,  test  sensitivity  was  included  in  the 
model  because  not  all  actual  positive  specimens  gave  positive 
results due to the insensitivity of PCR reagent and unpredictable 
errors in experimental operations and instruments; D, proportion 
of true pandemic (H1N1) 2009 cases for which specimens were 
successfully collected; E, proportion of true positive specimens that 
were correctly identified by PCR reagent. ILI, influenza-like illness.
Table 1. Parameter values and sources of data included in the multiplier model for estimating the true number of persons infected with 
pandemic (H1N1) 2009, Beijing*† 
Code  Parameter  Value, %  Source
A Proportion of symptomatic infection among case-patients 
with pandemic (H1N1) 2009 
70–75  Pandemic (H1N1) 2009, ECDC Risk 
Assessment.,2009; version 6, 6 Nov. 
B Proportion of ILI among symptomatic case-patients with 
pandemic (H1N1) 2009 
26–42  Literature and unpublished clinical data
C1 (period 2a)  Consultation rate among ILI case-patients in secondary 
and tertiary hospitals 
38 Telephone interview conducted by 
Beijing CDC 
C2 (period 2b)  Consultation rate among ILI case-patients in secondary 
and tertiary hospitals 
48 Telephone interview conducted by 
Beijing CDC 
D Sampling success rate  80–90  Previous surveillance data 
E Sensitivity of test  95–100  Professional recommendations 
*ECDC, European Centre for Disease Prevention and Control; ILI, influenza-like illness; Beijing CDC, Beijing Center for Disease Prevention and Control. 
†The multiplier model was only used for phase 2 in this study, and phase 2 was divided into 2 periods, period 2a and period  2b. During phase 2, the true 
number of infections was calculated by multiplying the baseline by the estimation coefficient, using the multiplier model. The baseline case number was 
equal to the sum of product of weekly ILIs number in level 2/3 hospitals and the corresponding weekly pandemic (H1N1) 2009 positive rate among case-
patients with ILIs. The estimation coefficient was obtained by multiplying the reciprocal of the parameters mentioned in this table. 
The baseline case numbers in periods 2a and 2b were 6,520 and 171,899, respectively. 2009 cases was estimated to be ≈1.01 to1.18 million. At the 
same time, the number of infections was estimated at 0.87–
1.28 million as of November 13, 2009, by the multiplier 
model (data not shown in the section of the study). The 
estimates of the infection matched with the actual number 
estimated from the serologic survey in principle.
In phase 1, the number of laboratory-confirmed cases 
was considered to reflect the true infection number. This 
assumption, however, may lead to an underestimation for 2 
reasons. First, we ignored the parameters used in phase 2, 
and second, difficulties occurred in testing all of the sam-
ples taken from patients who sought consultation for ILIs. 
Nevertheless, because the pandemic did not spread in the 
community in phase 1, we believe that this underestimation 
would have been quite low.
Although,  in  theory,  serologic  surveys  should  pro-
vide an accurate record of the infection rate of pandemic 
(H1N1) 2009, they failed to provide a quicker and more 
representative result than the multiplier model. Given the 
similarities between the estimates obtained from the model 
and the estimates obtained from the serologic survey, we 
conclude  that  the  multiplier  model  based  on  the  Monte 
Carlo approach should be considered a useful and simple 
method for estimating the true number of infections during 
a pandemic.
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Table 2. Estimated numbers of persons infected with pandemic (H1N1) 2009 and infection rate, by age group, Beijing* 
Age group, y 
Proportion of total no. 
persons infected, %  Estimated no. cases, median (90% CI)  Estimated rate, %, median (90% CI) 
0–4 13.4 241,253 (195,910–307,571)  30.8 (25.0–39.2) 
5–14  35.1 632,300 (513,459–806,111)  31.8 (25.8–40.6) 
15–24  29.4 528,597 (429,247–673,902)  22.2 (18.0–28.3) 
25–59  20.9 375,383 (304,829–478,571)  4.1 (3.3–5.2) 
>60 1.3 22,865 (18,568–29,150)  0.9 (0.7–1.1) 
Total 100.0  1,800,399 (1,462,012–2,295,305)  10.6 (8.6–13.5) 
*CI, confidence interval. 